Further, to understand whether CENPK can complement CA125 or HE4 to improve the sensitivity of clinical outcomes of ovarian cancer patients, combinations of two- and three-gene models were analyzed using the Kaplan–Meier survival analysis. This evidence concerns the gene MUC16 and ovarian cancer.